Bortezomib (Bortezomib) Patent Expiration, LOE Window & CMS Spending

Bortezomib (Bortezomib) by Pfizer: FDA Orange Book LOE 2042-09-23, 16 AB generics, $10.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN209191 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-09-23
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$10.0M
2024 Medicare Part D Spend$3.1M
2024 Medicaid Spend$6.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.